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SUMMARY: Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve
pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this
retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent
infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD
were evaluated during 9 – 42 days postpartum (mean = 31 days) and were divided into two groups: Group I — 14 newborns that did not receive
dexamethasone, and Group II — 12 newborns that received dexamethasone at 14 –21 days of life. Dexamethasone was given at a dose of 0.25 mg per
kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered.
Results - There were no statistically significant differences in the mean length of mechanical ventilation (Group I — 37 days, Group II — 35 days);
oxygen supplementation (Group I — 16 days, Group II — 29 days); hospital stay (Group I — 72 days, Group II — 113 days); mortality (Group I —
35.7%, Group II — 41.6%).
At birth, Group II was lighter (BW: Group I — 1154 grams ± 302, Group II — 791 grams ± 165; p < 0.05) and smaller (height: Group I — 37.22
cm ± 3.3, Group II — 33.5 ± 2.4; p< 0.05) than Group I.
At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements.
Conclusions - The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its
suspension, a recovery seems to occur, suggesting that its influence could be transitory.
DESCRIPTORS: Dexamethasone therapy. Bronchopulmonary dysplasia.
Corticosteroids have been used to
treat premature infants with bronchop-
ulmonary dysplasia. Possible mecha-
nisms of corticosteroid action include:
stabilization of cell and lysosomal
membranes1, increment of surfactant
synthesis2, inhibition of prostaglandin
and leukotriene synthesis3, decrease in
polymorphonuclear cell recruitment to
the lung4,5, enhancement of beta adren-
ergic activity6, reduction of pulmonary
and bronchial interstitial fluid7.
Several randomized clinical trials
of postnatal corticosteroids in prema-
ture infants with bronchopulmonary
dysplasia have been performed8–21. De-
spite a variety of study designs, some
studies report that corticosteroids im-
prove pulmonary compliance and fa-
cilitate extubation10,11,15,18, reduce the
use of mechanical ventilation 8–17 and
the length of oxygen therapy11,13,14,16,19.
Besides other adverse effects, re-
duced growth13,15,17 has been described
as a consequence of corticosteroid
treatment.
The purpose of the present study
was to analyze the influence of corti-
costeroid therapy on the outcome and
growth of premature infants with bron-
chopulmonary dysplasia.
PATIENTS  AND  METHOD
A retrospective study was carried
out at the Nursery Annexed to the Ma-
ternity, at the University of São Paulo
School of Medicine, from January
1993 to December 1997.
Inclusion criteria: All ventilator-de-
pendent very low birth weight infants
admitted to the BAM-HC, with bron-
chopulmonary dysplasia (oxygen de-
pendency at 28 days of life and clini-
cal and radiologic findings)22 and ges-
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tational age under 37 weeks were eli-
gible for the study.
Dexamethasone schedule: The ven-
tilator-dependent very low birth weight
infants were scheduled to receive dex-
amethasone at 14–21 days of life.
Starting in 1993, dexamethasone
was administered intravenously every
12 hours for 42 days, according to the
following schedule: 0.5 mg/kg/day
(days 1–3), then tapered by 10% of
initial dose every three days until 0.1
mg/kg/day.
Starting in 1995, dexamethasone
was administered at a dose of 0.5 mg/
kg/day for 3 days per week from the
14th day of life until 36 weeks post-
conceptual age or the termination of
mechanical ventilation or oxygen
therapy.
Starting in November 1997, dex-
amethasone was administered every 12
hours for 9 days, according to the fol-
lowing schedule: days 1 to 3 from the
14th day of life — 0.3 mg/kg/day; days
4 to 6 — 0.2 mg/kg/day; and days 7
to 9 — 0.15 mg/kg/d.
The preterm infants enrolled in the
study were subdivided into two groups:
Group I — without corticosteroid ad-
ministration, and Group II — with cor-
ticosteroid administration.
Gestational age was determined by
the date of the last normal menstrual
period, and verified by clinical evalu-
ation using the Dubowitz method23.
When the clinical assessment differed
from the calculated gestational age by
two weeks or more, the definitive ges-
tational age was based on clinical as-
sessment. Infants were classified as ad-
equate for gestational age (AGA) if
their birth weights were below the 90th
percentile and above the 10th percentile
on the Ramos intrauterine growth
curve24, and small for gestational age
if their birth weights were below the
10th percentile on the same curve25.
The primary outcome measures
were: the time of extubation, length of
mechanical ventilation and supplemen-
tal oxygen, hospital stay, and rate of
mortality.
The secondary outcome measure
was the pattern of growth.
Chest X-ray studies were per-
formed on admission, as clinically in-
dicated, and at 28 days of life.
Anthropometric measurements
were performed at birth and once per
week of infant life until discharge.
Weight was measured with the infant
naked on an electronic scale (Filizzola,
São Paulo) to the nearest gram (g).
Crown-heel length was measured with
the person holding the head of the in-
fant using a wooden measuring board
with a fixed headboard and a movable
foot board (cm). Cephalic circumfer-
ence (largest occipito-frontal circum-
ference) was measured with a glass fi-
ber measuring tape (cm).
STATISTICAL  ANALYSIS
Data were entered into Epi Info
6.04 for analysis. Group differences
were analyzed with the use of
Student’s T and Mann-Whitney tests
for continuous variables and chi-square
test for discrete variables. To control
potentially confounding variables, a
stratified analysis for birth weight and
gestational age was done.
Growth rates were estimated by
comparisons of means (Student’s T
test) for weight, length, and cephalic
circumference at birth, 36, and 40
weeks postconceptual age.
RESULTS
During the period of study, among
the 1065 infants with respiratory insuf-
ficiency, 35 (3.3%) developed bron-
chopulmonary dysplasia, and 26 (80%)
of these were enrolled in the study.
Infants with bronchopulmonary
dysplasia were subdivided into two
groups: Group I — infants that did not
receive corticosteroids (14 infants), and
Group II — infants that were treated
with corticosteroids (12 infants).
Group II was smaller (p< 0.05) and
younger (p< 0.05) (Table 1). Other
population characteristics in the two
groups were similar (sex; color; ante-
natal corticosteroid therapy; five-
minute Apgar score < 6; inhalation
therapy with b2 adrenergic , furo-
semide, and aminophylline) (Table 1).
There were no differences in the
Table 1 - Population characteristics.
Group I ( n=14) Group II (n = 12) Whole ( n=26)
Birth weight (g) 1154.28* ± 30239 791.66* ± 16579 966.92
Gestational age (weeks)  31** ± 219  29** ± 185  301
Male/Female  10/4  8/4  18/8
White/ No White  10/4  8/4  18/8
SGA/AGA  10/4  8/4  18/8
5–minute Apgar< 6  42%  58%  50%
Aminophylline  100%  100%  100%
Furosemide  86%  84%  85%
b2–adrenergic  14.3%  50%  43%
Antenatal corticosteroid  21%  25%  23.1%
p < 005 **p< 005
SGA - small for gestational age AGA - adequate for gestational age
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number of days of mechanical ventila-
tion, oxygen requirement, length of
hospital stay (Fig 1), and death rates
(Group I — 35.% and Group II —
41.6%) between the groups studied.
At birth, the group that received
corticosteroids (Group II) was lighter
(birth weight : Group I — 1154 g ±
302, Group II — 791g ± 165; p< 0.05)
(Fig 2) and smaller (height : Group I
– 37.22 cm ± 3.3, Group II – 33.5 cm
± 2.4 , p< 0.05) (Fig 3) than the non-
steroid treated group (Group I).
Because Group II was lighter and
younger, stratified analysis was done
(BW < = 1120 g and > 1120, GA < 32
weeks and > 32 weeks). There were no
differences between groups in relation
to variables analyzed (length of time
ventilation, CPAP, oxygen therapy,
length of hospital stay, and death
rates). Therefore, the differences
among groups in birth weight and ges-
tational age did not influence the re-
sults.
At 36 weeks, the infants in Group
II were lighter than those in Group I
(weight: Group I — 1247 g ± 308,
Group II — 965 g ± 134, p < 0.05)
(Fig 2). At 40 weeks, there were no
differences in weight and height be-
tween the groups (Fig 3). Concerning
cephalic circumference, there was no
difference between the groups (Fig 4).
At 40 weeks, both groups had weights
below a -5.00 Z score, and had heights
below a -9.48 Z score.
DISCUSSION
This study shows that corticoster-
oids given to infants with bronchopul-
monary dysplasia that were ventilator-
dependent did not change the length of
mechanical ventilation, CPAP, and
oxygen therapy. Also, dexamethasone
therapy did not reduce mortality or
length of hospitalization. As all infants
were undergoing mechanical ventila-
tion at 36 weeks postconceptual age,
Figure 2 - Weight (g) at birth, 36 and 40 weeks postconceptual of newborns with BPD (Ramos,
1983).
Days of life
Figure 1 - Neonatal outcome of infants with bronchopulmonary dysplasia.
LMS - Length of hospitalization stay; O2 - oxygen therapy duration; CPAP - continuous
positive airway pressure; MV - mechanical ventilation.
corticosteroids probably did not
modify the severity of the disease.
Several limitations of this study re-
quire further discussion. The corticos-
teroid group was lighter and younger
than control group, and this could have
influenced the outcome measures used
in this study. However, after controlling
for birth weight and gestational age in
the stratified analysis, corticosteroid
management did not affect the primary
outcome measures in this study.
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ethasone on growth rates are possibly
transitory.
Many studies have provided evi-
dence of acute improvement in lung
function — increase in dynamic lung
compliance10,15,18 and easier, earlier ex-
tubation10,11,13–18,26 — when corticoster-
oids were used.
Corticosteroids have been used to
prevent or treat bronchopulmonary
dysplasia since 19788, and now they
are increasingly being used, probably
because of their anti-inflammatory ac-
tivity.
The studies concerning systemic
corticosteroid use for prevention or
treatment of bronchopulmonary dys-
plasia can be subdivided according to
the postnatal age at onset of treatment:
early — 96 hours, moderately early —
7 to 14 days, and delayed — > 3
weeks27.
Studies with moderately early on-
set of systemic corticosteroid use
showed a significant reduction in neo-
natal mortality up to 28 days postpar-
tum, and a significant reduction in
chronic lung disease at both 28 days
postpartum and 36 weeks post-concep-
tion. Also observed were an earlier ex-
tubation, and the infants were less
likely to require late treatment with
dexamethasone11,19,28.
Studies with delayed onset of treat-
ment with systemic corticosteroids
showed only earlier extubation and re-
duced length of oxygen therapy. How-
ever, they showed no effects on mor-
tality10,13,14,16,17.
The absence of improvement in the
respiratory conditions, length of hospi-
tal stay, and mortality seen in this study
could be explained, in part, by the time
of onset of corticosteroid therapy —
between 14 and 21 days postpartum —
which is between the moderately early
groups and the delayed groups re-
ported in the literature.
Several studies showed that dexam-
ethasone delays growth rate13,15,17, and
one study also has shown a significant
Figure 4 - Cephalic circumference (cm) at birth, 36 and 40 weeks postconceptual of newborns with
BPD (Ramos, 1983).
Figure 3 - Length (cm) at birth, 36 and 40 weeks postconceptual of newborns with BPD (Ramos,
1983).
Concerning somatic growth, al-
though the infants treated with corti-
costeroids were lighter and smaller at
birth than infants that did not receive
corticosteroids, we observed that after
suspension of dexamethasone use, the
somatic growth rates of treated infants
recovered, so that at 40 weeks, their
anthropometric measurements did not
differ significantly from the infants
that did not receive corticosteroids.
Therefore, adverse effects of dexam-
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decline in the growth of cephalic cir-
cumference26. Dexamethasone treat-
ment resulted in increased amino acid
oxidation and decreased muscle protein
synthesis in the piglet model29. Others
did not observe influence of corticos-
teroids on growth30.
In summary, the use of corticoster-
oids in bronchopulmonary dysplasic
infants appeared to impair somatic
growth during its use. However, after
its suspension, a growth recovery was
detected, supporting the hypothesis that
growth-related corticosteroid effects
could be transitory.
RESUMO RHCFAP/2988
MATALOUN, MMGB e col. – Uso de
Corticosteróides e evolução de
recém-nascidos com displasia
broncopulmonar. Rev. Hosp. Clín.
Fac. Med. S. Paulo 54 (6): 175-
180, 1999.
Recém-nascidos (RN) pré-termo
dependentes de ventilação mecânica
são frequentemente, tratados com corti-
costeróides. Vários estudos demonstra-
ram que o uso de corticosteróides me-
lhora a complacência pulmonar e faci-
lita a extubação. No entanto, o uso de
corticosteróides é associado , também,
a alguns efeitos colaterais, como alte-
rações na curva de crescimento dos re-
cém-nascidos. Nós realizamos um es-
tudo retrospectivo, para avaliar os efei-
tos dos corticosteróides sobre a dura-
ção da ventilação mecânica, oxigeno-
terapia como também sobre o tempo de
internação e mortalidade, em recém-
nascidos com displasia broncopul-
monar dependentes de ventilação me-
cânica (DBP) (definida como necessi-
dade de suplementação de oxigênio até
28 dias de vida). Foram analisados 26
RN com DBP e divididos em 2 grupos:
grupo I – 14 RN, que não receberam
dexametasona e grupo II – 12 RN que
receberam dexametasona a partir de 14
a 21 dias de vida, durante 9 a 42 dias
( média – 31 dias). Administrou-se
dexametasona, endovenosa, em uma
dose inicial de 0,25 mg/kg dividida em
duas tomadas durante 3 dias, e após di-
minuiu-se a dose até suspensão.
Resultados: Não se observou dife-
renças significantes em relação à dura-
ção da ventilação mecânica (grupo I-
37 dias e grupo II – 35 dias),
suplementação de oxigênio (grupo I –
16 dias e grupo II – 29 dias), tempo de
permanência no hospital (grupo I – 72
dias , grupo II – 113 dias), e mortali-
dade (grupo I – 35,7%, grupo II –
41,6%).
O grupo II tinha menor peso de
nascimento ( PN- Grupo I – 1154 gra-
mas ± 302 e grupo II – 791 gramas ±
165; p< 0,05) e menor comprimento ao
nascimento (Comprimento- grupo I-
37,22 ± 3,3 e grupo II – 33,5 ± 2,4;
p < 0,05) em relação ao grupo I. Com
40 semanas, não se observou diferen-
ças significantes entre os grupos com
relação às medidas antropométricas.
Conclusão: O uso de corticos-
teróides em RN com displasia bronco-
pulmonar, pode influenciar o cresci-
mento somático durante o seu uso. No
entanto, após sua suspensão parece
ocorrer uma recuperação do cresci-
mento, sugerindo que sua influência
pode ser transitória.
DESCRITORES: Dexametasona.
Displasia broncopulmonar.
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